Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Uwe Platzbecker; Rami S. Komrokji; Pierre Fenaux; Amer M. Zeidan; Mikkael A. Sekeres; Michael Robert Savona; Yazan F. Madanat; Valeria Santini; Koen Van Eygen; Azra Raza; Ulrich Germing; Tymara Berry; Souria Dougherty; Sheetal Shah; Libo Sun; Fei Huang; Faye Feller; Ying Wan; Annat Ikin; Laurie Sherman

doi:10.1182/blood-2022-169050

$Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study$

Journal article

Peer reviewed

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Uwe Platzbecker, Rami S. Komrokji, Pierre Fenaux, Amer M. Zeidan, Mikkael A. Sekeres, Michael Robert Savona, Yazan F. Madanat, Valeria Santini, Koen Van Eygen, Azra Raza, …

Blood, Vol.140(Supplement 1), pp.1106-1108

2022-11-15

DOI: https://doi.org/10.1182/blood-2022-169050

Appears in Miller School of Medicine - Latest Publications

Metrics

7 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.155 Acute Myeloid Leukemia
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
Creators: Uwe Platzbecker - University Hospital Leipzig
Rami S. Komrokji - Moffitt Cancer Center
Pierre Fenaux - Paris 8 University
Amer M. Zeidan - Yale University
Mikkael A. Sekeres - Sylvester Comprehensive Cancer Center
Michael Robert Savona - Vanderbilt University Medical Center
Yazan F. Madanat - Southwestern Medical Center
Valeria Santini - University of Florence
Koen Van Eygen - Southwestern Medical Center
Azra Raza - Presbyterian Hospital
Ulrich Germing - Düsseldorf University Hospital
Tymara Berry - 13Geron Corporation, Parsippany,
Souria Dougherty - 13Geron Corporation, Parsippany,
Sheetal Shah - 13Geron Corporation, Parsippany,
Libo Sun - 13Geron Corporation, Parsippany,
Fei Huang - 13Geron Corporation, Parsippany,
Faye Feller - 14Geron Corporation, Parsippany, NJ
Ying Wan - 14Geron Corporation, Parsippany, NJ
Annat Ikin - 13Geron Corporation, Parsippany,
Laurie Sherman - 14Geron Corporation, Parsippany, NJ
Publication Details: Blood, Vol.140(Supplement 1), pp.1106-1108
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031760102002976